adult vaccine recommended by the Advisory Committee on Immunization Practices
(8) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices consistent with treatment of vaccines under part B (A) In general For plan years beginning on or after January 1, 2023 , with respect to an adult vaccine recommended by the Advisory Committee on Immunization Practices (as defined in subparagraph (B))— (i) the deductible under paragraph (1) shall not apply; and (ii) there shall be no coinsurance or other cost-sharing under this part with respect to such vaccine. (B) Adult vaccines recommended by the Advisory Committee on Immunization Practices For purposes of this paragraph, the term “adult vaccine recommended by the Advisory Committee on Immunization Practices” means a covered part D drug that is a vaccine licensed under section 351 of the Public Health Service Act [ 42 U.S.C. 262 ] for use by adult populations and administered in accordance with recommendations of the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention.